A carregar...
Cost Analysis of a Novel Enzymatic Debriding Agent for Management of Burn Wounds
Introduction. Given its efficacy and safety, NexoBrid™ (NXB) has become part of our therapeutic options in burns treatment with satisfactory results. However, no cost analysis comparing NXB to the standard of care (SOC) has been carried out as of today. Aim. To assess the cost of treatment with NXB...
Na minha lista:
| Publicado no: | Biomed Res Int |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi Publishing Corporation
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5331316/ https://ncbi.nlm.nih.gov/pubmed/28293640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2017/9567498 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|